Clinical Study of Efficacy of Interferon .ALPHA. for chronic hepatitis C. Evaluation according to Effectiveness and Background.

Toyoda, Hidenor; Nakano, Satoshi; Kumada, Takashi; Takeda, Isao; Sugiyama, Keiichi; Osada, Toshimasa; Kiriyama, Seiki; Suga, Takashi; Ohki, Hayato; Ito, Osamu; Ebata, Mituo; Takahashi, Mikako

doi:10.2957/kanzo.35.481

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We therefore carried out a controlled study in which all patients were dosed according to the basic Japanese treatment schedule, but group A received 6x10 6 of IFN six days per week through the initial two-week treatment period while group B received 9x10 6 U; both groups then received 6x10 6 three times a week for the remaining 22 weeks. The total IFN dose was thus 468x10 6 U in group A and 504x10 6 in group B, a fairly modest difference. We hypothesized, however, that the higher initial dose would have a favourable effect on response to treatment.…”

Section: Discussionmentioning

confidence: 99%

“…In group A, 6x10 6 U IFNa-2a was administered six days per week for two weeks, followed by the same dose three days per week for 22 weeks. The total dose of IFN was 468x10 6 U. In group B, the initial dose was 9x10 6 U six days per week for two weeks, followed by the same regimen of 6x10 6 U three days per week for 22 weeks, as per group A.…”

Section: Methodsmentioning

confidence: 99%

“…The total dose of IFN was 468x10 6 U. In group B, the initial dose was 9x10 6 U six days per week for two weeks, followed by the same regimen of 6x10 6 U three days per week for 22 weeks, as per group A. The total dose of IFN was 504x10 6 U.…”

Section: Methodsmentioning

confidence: 99%

“…The Japanese treatment regimen has proven effective: although the percentage of patients with long term normalization of transaminase levels is relatively low -about 30% (5,6) -the rarity of spontaneous recovery in hepatitis C patients renders this a very significant improvement in clinical outcome. IFN treatment is expensive, however, and is associated with various adverse reactions.…”

mentioning

confidence: 99%

See 3 more Smart Citations

A Multicentre Randomized Controlled Trial of Recombinant Interferon-Alpha-2a in the Treatment of Patients with Chronic Hepatitis C

Komatsu

Ono

Nakajima

et al. 1997

Canadian Journal of Gastroenterology

View full text Add to dashboard Cite

Sixty-one chronic hepatitis C patients were randomly assigned to receive either 6 x 10(6) or 9 x 10(6) U of recombinant interferon-alpha-2a (IFN alpha-2a) six days a week for the first two weeks of treatment, followed in both cases by 6 x 10(6) U three days a week for the next 22 weeks. In the low dose group, 11 patients showed a complete response maintained for at least six months, 12 responded but then relapsed and nine did not respond; the corresponding figures in the high dose group were 10, 15 and five patients, respectively. The differences between groups are not statistically significant. Thus, this study provides no evidence of therapeutic benefit from increasing the initial dose of IFN alpha-2a. In both treatment groups, complete responders had significantly lower pretreatment viral titres than nonresponders and were significantly more likely to be infected by type 2a versus type 1b virus.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

A Multicentre Randomized Controlled Trial of Recombinant Interferon-Alpha-2a in the Treatment of Patients with Chronic Hepatitis C

Komatsu

Ono

Nakajima

et al. 1997

Canadian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

Efficacy and side effects of intermittent recombinant interferon‐α2a in chronic aggressive hepatitis C: With or without initial daily administration

Itoh

Nakata

Yokoya

et al. 1996

J of Gastro and Hepatol

View full text Add to dashboard Cite

To investigate the therapeutic effect and incidence of side effects of recombinant interferon-alpha 2a (IFN-alpha) in chronic aggressive hepatitis C under stratification by administration mode, a study was conducted by assigning patients to either group A (daily consecutive administration of 9 million units (MU) IFN-alpha for 2 weeks and, thereafter, 3 MU intermittently 3 times weekly for 22 weeks) or group B (exclusively intermittent administration; 9 MU IFN-alpha twice weekly or 6 MU IFN-alpha thrice weekly for 24 weeks). The 28 patients in group A received IFN-alpha for 24 weeks up to a total dose of 324 MU and the 53 patients in group B received the same for 24 weeks up to a total dose of 432 MU. When recovery was defined as the absence of hepatitis C virus (HCV)-RNA 6 months after the completion of treatment, the rate of recovery for group A was 32.1% and that for group B was 37.7%, the latter being higher but without significance. Side effects in groups A and B consisted of leucopenia occupying 14.3 and 7.5%, respectively, and thrombocytopenia occupying 42.9 and 11.3%, respectively; group B exhibited lower values for both side effects. No difference was detected between these groups in other side effects, including pyrexia, generalized malaise, arthralgia or psilosis. Intermittent administration from the outset permitted shortened duration of hospitalization and earlier rehabilitation. Intermittent administration of INF-alpha is required when treating patients with chronic hepatitis C showing lower leucocyte or platelet counts.

show abstract

Detection of hepatocellular carcinoma after interferon therapy for chronic hepatitis C: Clinical study of 26 cases

Sugiura

Sakai

Ebara

et al. 1996

J of Gastro and Hepatol

View full text Add to dashboard Cite

The clinical findings in 26 patients in whom hepatocellular carcinoma (HCC) was detected after the start of interferon (IFN) therapy for chronic hepatitis C were analysed. Histological study before IFN therapy showed that 34.6% of patients were categorized as stage 3 (septal fibrosis with architectural distortion; the 0-4 scale) and 80.8% demonstrated at least some evidence of septal fibrosis or more advanced features. The AFP levels examined before IFN therapy were more than 20 ng/mL in 13 patients (84.6% of those studied). One of 26 patients had a complete response to IFN therapy, while six of 26 patients had only a partial response. HCC was detected within 1 year after the start of IFN therapy in 76.9% of patients. Thus, the possibility of the early occurrence of HCC or its existence at the time of therapy should be seriously considered when IFN therapy is contemplated. Patients with stage 3 or 3-4 histology may already have a small undetectable HCC before IFN therapy. Thus, for this reason, every patient treated with IFN should be examined at short regular intervals for the development of HCC during and after IFN therapy.

show abstract

Clinical Study of Efficacy of Interferon .ALPHA. for chronic hepatitis C. Evaluation according to Effectiveness and Background.

Cited by 4 publications

References 0 publications

A Multicentre Randomized Controlled Trial of Recombinant Interferon-Alpha-2a in the Treatment of Patients with Chronic Hepatitis C

A Multicentre Randomized Controlled Trial of Recombinant Interferon-Alpha-2a in the Treatment of Patients with Chronic Hepatitis C

Efficacy and side effects of intermittent recombinant interferon‐α2a in chronic aggressive hepatitis C: With or without initial daily administration

Detection of hepatocellular carcinoma after interferon therapy for chronic hepatitis C: Clinical study of 26 cases

Contact Info

Product

Resources

About